Activity of Doxorubicin Covalently Bound to a Novel Human Serum Albumin Microcapsule

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Investigational new drugs

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1023/A:1006362915317PMID 10638482
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transport of molecules across tumor vasculature

  2004cited by this paper
• Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.

  1998cited by this paper
• Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

  1997cited by this paper
• Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action.

  1997cited by this paper
• Clinical trials of P-glycoprotein reversal in solid tumours.

  1996cited by this paper
• Targeted cancer chemotherapy with arterial microcapsule chemoembolization: review of 1013 patients

  1996cited by this paper
• Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell.

  1995cited by this paper
• Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells.

  1995cited by this paper
• Characterization of the Mr 190,000 Multidrug Resistance Protein (MRP) in Drug-selected and Transfected Human Tumor Cells

  1995cited by this paper
• Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.

  1995cited by this paper
• Multidrug resistance bypass in cells exposed to doxorubicin-loaded nanospheres. Absence of endocytosis.

  1995cited by this paper
• Endocytosis does not necessarily augment the cytotoxicity of adriamycin encapsulated in immunoliposomes.

  1994cited by this paper
• Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression.

  1994cited by this paper
• Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines.

  1994cited by this paper
• Some parameters influencing cytotoxicity of free doxorubicin and doxorubicin-loaded nanoparticles in sensitive and multidrug resistant leucemic murine cells: incubation time, number of nanoparticles per cell

  1994cited by this paper
• An in vivo assessment of adriamycin-loaded albumin microspheres.

  1992cited by this paper
• Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors.

  1992cited by this paper
• A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients

  1992cited by this paper
• Covalent coupling of doxorubicin in protein microspheres is a major determinant of tumour drug disposition.

  1991influential reference
• Angiotensin II as a potential method of targeting cytotoxic-loaded microspheres in patients with colorectal liver metastases.

  1991cited by this paper
• Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.

  1990cited by this paper
• Albumin microspheres. I: Physico-chemical characteristics.

  1989cited by this paper
• Effect of particle size on the in vitro and in vivo degradation rates of poly(DL-lactide-co-glycolide) microcapsules.

  1988cited by this paper
• Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells.

  1988cited by this paper
• Enhancement of Adriamycin Antitumor Activity by Its Binding with an Intracellular Sustained-Release Form, Polymethacrylate Nanospheres, in U-937 Cells1 Alain Astier,2 Bénédicte Doat, Marie-Jeanne Ferrer, Guy Benoit, Jocelyne Fleury, Alain Rolland, and Roger Leverge

  1988cited by this paper
• Influence of Stabilization Temperature on the Entrapment of Adriamycin in Albumin Microspheres

  1987cited by this paper
• Increased anti-tumor effect of adriamycin-loaded albumin microspheres is associated with anaerobic bioreduction of drug in tumor tissue.

  1987cited by this paper
• A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

  1986cited by this paper
• Transport of Macromolecules In Tumor Microcirculation

  1985cited by this paper
• Cell surface effects of adriamycin and carminomycin immobilized on cross-linked polyvinyl alcohol.

  1985cited by this paper
• Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.

  1983cited by this paper
• The anticancer agent adriamycin can be actively cytotoxic without entering cells.

  1982cited by this paper
• A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.

  1982cited by this paper
• Degradation of side-chains ofN-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases

  1982cited by this paper
• Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.

  1982cited by this paper

• Evaluation of the selective toxic effect of the charge switchable diethyldithiocarbamate-loaded nanoparticles between hepatic normal and cancerous cells

  2018cites this paper
• Enhanced tumor delivery and antitumor response of doxorubicin-loaded albumin nanoparticles formulated based on a Schiff base

  2016cites this paper
• Highly water-dispersible TiO2 nanoparticles for doxorubicin delivery: effect of loading mode on therapeutic efficacy

  2011cites this paper
• In vitro and biodistribution examinations of Tc-99m-labelled doxorubicin-loaded nanoparticles.

  2011cites this paper
• Serum Proteins as Drug Carriers of Anticancer Agents

  2011cites this paper
• Parenteral Formulations Based on Albumin Particulate Technology

  2010cites this paper
• Adsorption of obidoxime onto human serum albumin nanoparticles: Drug loading, particle size and drug release

  2010cites this paper
• Evaluation of Arsenic Trioxide-Loaded Albumin Nanoparticles as Carriers: Preparation and Antitumor Efficacy

  2008cites this paper
• Changes produced by external radiation in parameters influencing intestinal permeability and microparticle uptake in vitro

  2008cites this paper
• Uptake of inert microparticles in normal and immune deficient mice.

  2008cites this paper
• Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles.

  2007cites this paper
• Factors influencing intestinal microparticle uptake in vivo.

  2007cites this paper
• Effect of reproductive status on uptake of latex microparticles in rat small intestine.

  2005cites this paper
• Evaluation of microparticles containing doxorubicin suitable for aerosol delivery to the lungs.

  2004cites this paper
• Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin

  2002cites this paper
• Investigation of cellular and molecular mechanisms involved in targeted drug delivery systems for human cancers

  2002cites this paper
• Literature alerts.

  2000cites this paper